Download PDF
Thromb Haemost 1980; 44(02): 072-075
DOI: 10.1055/s-0038-1650087
Original Article
Schattauer GmbH Stuttgart

Increased Fibrinopeptide A after Prothrombin Complex Concentrates

S Viganó
The Hemophilia and Thrombosis Centre Angelo Bianchi Bonomi, University of Milano, Italy
,
M Cattaneo
The Hemophilia and Thrombosis Centre Angelo Bianchi Bonomi, University of Milano, Italy
,
W Gervasoni
The Hemophilia and Thrombosis Centre Angelo Bianchi Bonomi, University of Milano, Italy
,
P M Mannucci
The Hemophilia and Thrombosis Centre Angelo Bianchi Bonomi, University of Milano, Italy
› Author Affiliations
Further Information

Publication History

Received 02 May 1980

Accepted 12 August 1980

Publication Date:
13 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Prothrombin complex concentrates (PCC) are known to carry a risk of thromboembolism. We have chosen to reassess the problem of detecting in vivo signs of activation of the clotting mechanism by assaying fibrinopeptide A (FpA) after PCC administration in hemophilic patients during bleeding episodes. FpA was significantly increased above baseline levels 15 to 60 min after the infusion of 19 doses of 5 different types of commercial PCC in 14 hemophilia B patients treated for bleeding episodes or dental extractions. A more marked increase followed 16 infusions of the activated PCC FEIBA and Auto IX in 4 hemophilia A patients with F. VIII inhibitors. There was no significant FpA change after F. VIII concentrates administred to a control group of 7 patients with hemophilia A. These findings suggest that circulation of thrombin occurs frequently after PCC administration, even though clinical manifestations of thromboembolism appear to be relatively rare.

Key words

Prothrombin complex concentrates - Hemophilia - Thrombogenicity - Fibrinopeptide A
 

  • References

  • 1 Kasper CK. Thromboembolic complication. Thromb Diath Haemorrh 1975; 330: 640-644
    PubMedGoogle Scholar
  • 2 Kingdon HS, Lundblad RL, Veltkamp JJ, Aronson DL. Potentially thrombogenic materials in factor IX concentrates. Thromb Diath Haemorrh 1975; 33: 617-631
    PubMedGoogle Scholar
  • 3 White GC, Roberts HR, Kingdon HS, Lundblad RL. Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo. Blood 1977; 49: 159-170
    PubMedGoogle Scholar
  • 4 Sas G, Owens RE, Smith JK, Middleton S, Cash JD. In vitro spontaneous thrombin generation in human factor-IX concentrates. Br J Haemat 1975; 31: 25-35
    CrossrefPubMedGoogle Scholar
  • 5 Prowse CV, Pepper DS, Cash JD, Patterson M. Thrombogenicity screening of factor IX concentrates. Thromb Haemostas 1977; 38: 728-729
    PubMedGoogle Scholar
  • 6 Cash JD, Owens R, Dalton RG, Prescott RJ. Thrombogenicity of factor IX concentrates: in vitro (Rabbit) studies. Vox Sang 1978; 35: 105-110
    CrossrefPubMedGoogle Scholar
  • 7 Cash JD, Dalton RG, Middleton S, Smith JK. Studies on the thrombogenicity of Scottish factor IX concentrates in dogs. Thromb Diath Haemorrh 1975; 33: 632-639
    PubMedGoogle Scholar
  • 8 Hedner U, Nilsson IM, Bergentz JE. Various prothrombin complex concentrates and their effect on coagulation and fibrinolysis in vivo. Thromb Haemostas 1976; 35: 386-394
    PubMedGoogle Scholar
  • 9 Green G, Dymock IW, Poller L, Thomson JM. Use of factor IX rich prothrombin complex concentrate in liver disease. Lancet 1975; 1: 1311-1313
    PubMedGoogle Scholar
  • 10 Mannucci PM, Franchi F, Dioguardi N. Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet 1976; 2: 542-545
    PubMedGoogle Scholar
  • 11 Preston FE, Malia RG, Lilleman JS, Blackburn EK. Heparinized clotting factor concentrates in patients with Christmas disease and liver disease. Thromb Haemost 1977; 38: 504-509
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Blomback B, Vestermark A. Isolation of fibrinopeptides by chromatography. Ark Kemi 1958; 12: 173-178
    PubMedGoogle Scholar
  • 13 Nossel HL, Yudelman I, Canfiel RE, Butler Jr VP, Spanondis K, Wildner GD, Qureshi GD. Measurement of Fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53
    CrossrefPubMedGoogle Scholar
  • 14 Nossel HL, Ti M, Kaplan KL, Spanondis K, Solant T, Butler Jr VP. The generation of Fibrinopeptide A in clinical blood samples. Evidence for thrombin activity. J Clin Invest 1976; 58: 1136-1144
    CrossrefPubMedGoogle Scholar
  • 15 Kockum C. Radioimmunoassay of fibrinopeptide A. Clinical applications. Thromb Res 1976; 8: 225-236
    CrossrefPubMedGoogle Scholar
  • 16 Hofmann V, Straub PW. A radioimmunoassay technique for the rapid measurement of human fibrinopeptide A. Thromb Res 1977; 11: 171-181
    CrossrefPubMedGoogle Scholar
  • 17 Vermylen C, De Vreker RA, Verstraete M. A quick quantitative enzymatic fibrinogen assay method: the fibrin polymerization time (FPT). Clin Chim Acta 1963; 8: 418-424
    CrossrefPubMedGoogle Scholar
  • 18 Allington MJ. Fibrinogen and fibrin degradation products and the clumping of staphylococci. Br J Haematol 1967; 31: 550-567
    PubMedGoogle Scholar
  • 19 Abildgaard U, Lil M, Odegard OR. Antithrombin (heparin confactor) assay with a new chromogenic substrate. Thromb Res 1977; 11: 549-554
    CrossrefPubMedGoogle Scholar
  • 20 Godal HC, Abildgaard U. Gelation of soluble fibrin in plasma by ethanol. Scand J Haematol 1966; 3: 342-350
    PubMedGoogle Scholar
  • 21 Mannucci PM, Federici A, Viganò S, Cattaneo M. Multiple dental extractions with a new prothrombin complex concentrate in two patients with factor VIE inhibitors. Thromb Res 1979; 15: 359-364
    CrossrefPubMedGoogle Scholar
  • 22 Hofmann V, Straub PW. 8-hour radioimmunoassay for fibrinopeptide A (FPA). Thromb Haemostas 1977; 38: 59
    PubMedGoogle Scholar
  • 23 Elodi S, Varadi K. Activation of clotting factors in prothrombin complex concentrates as demonstrated by clotting assays for factors IXa and Xa. Thromb Res 1978; 12: 797-807
    CrossrefPubMedGoogle Scholar
  • 24 Chandra S, Wickerhauser M. Contact factors are responsible for the thrombogenicity of prothrombin complex. Thromb Res 1979; 14: 189-198
    CrossrefPubMedGoogle Scholar
  • 25 Hultin MB. Activated clotting factors in factor IX concentrates. Blood 1979; 5: 1028-1038
    PubMedGoogle Scholar
  • 26 Hofmann V, Ermanni M, Straub PW. Thrombinbildung in Faktor IX-Konzentraten und FEIBA (factor eight inhibitor bypassing activity). Schweiz Med Wschr 1978; 108: 1600-1601
    PubMedGoogle Scholar